Video abstract
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:
Background
The purpose of this study was to evaluate the safety and efficacy of ultraviolet A irradiation cross-linking on completion for cases of high myopic laser-assisted in situ keratomileusis (LASIK).
Methods
Forty-three consecutive LASIK cases treated with femtosecond laser flap and the WaveLight excimer platform were evaluated perioperatively for uncorrected visual acuity, best corrected spectacle visual acuity, refraction, keratometry, topography, total and flap pachymetry, corneal optical coherence tomography, and endothelial cell count. All eyes at the completion of LASIK had cross-linking through the repositioned flap, with higher fluence (10 mW/cm2) ultraviolet light of an average 370 μm wavelength and 10 mW/cm2 fluence applied for 3 minutes following an earlier single instillation of 0.1% riboflavin within the flap interface. Mean follow-up duration was 3.5 (range 1.0–4.5) years.
Results
Mean uncorrected visual acuity changed from 0.2 to 1.2, best corrected spectacle visual acuity from 1.1 to 1.2, spherical equivalent from −7.5 diopters (D) to −0.2 D, keratometry from 44.5 D to 38 D, flap pachymetry from 105 μm to, total pachymetry from 525 to 405, and endothelial cell count from 2750 to 2800. None of the cases developed signs of ectasia or significant regression during follow-up.
Conclusion
Prophylactic collagen cross-linking for high-risk LASIK cases appears to be a safe and effective adjunctive treatment for refractive regression and potential ectasia. This application may be viewed as prophylactic customization of the biomechanical behavior of corneal collagen.
Disclosure
Part of this work was presented as a paper at the American Academy of Ophthalmology annual meeting in San Francisco, CA, October 24–27, 2009, and as a poster at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 3–7, 2009. Otherwise, the author reports no conflict of interest in this work.